Achilles Transfers Technology Assets From TRACERx NSCLC Study To AstraZeneca For $12 Mln, Stock Up
Written by Emily J. Thompson, Senior Investment Analyst
Source: Business Insider
Commercial License Transfer: Achilles Therapeutics has transferred the commercial license of data and samples from its TRACERx Non-Small Cell Lung Cancer study to AstraZeneca for $12 million, which will also sponsor Achilles' Material Acquisition Platform.
Workforce Reduction: As part of a strategic review, Achilles Therapeutics plans to reduce its workforce and board size while its stock has seen a 10.20% increase, trading at $1.08 on Nasdaq.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
